{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:01:04Z","timestamp":1780333264489,"version":"3.54.1"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"crossref","award":["VBD\/NIMR\/Intra\/008-(E-OFFICE-205304) Dated 04\/11\/2024"],"award-info":[{"award-number":["VBD\/NIMR\/Intra\/008-(E-OFFICE-205304) Dated 04\/11\/2024"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discover Nano"],"DOI":"10.1186\/s11671-026-04695-3","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:02:33Z","timestamp":1780326153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ligand decorated nanostructure carrier systems for targeted delivery of antimalarials"],"prefix":"10.1186","volume":"21","author":[{"given":"Kuldeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Ranjha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem Akram","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mradul","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himmat","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Kumar","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup R.","family":"Anvikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"4695_CR1","doi-asserted-by":"crossref","unstructured":"Singh K, Bharti PK, Devi NC et al. Plasmodium malariae Detected by Microscopy in the International Bordering Area of Mizoram, a Northeastern State of India. Diagnostics (Basel). 2022;12(8).","DOI":"10.3390\/diagnostics12082015"},{"issue":"11","key":"4695_CR2","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1097\/MS9.0000000000002578","volume":"86","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU. Emerging public health strategies in malaria control: innovations and implications. Annals Med Surg. 2024;86(11):6576\u201384.","journal-title":"Annals Med Surg"},{"key":"4695_CR3","doi-asserted-by":"publisher","first-page":"e00244","DOI":"10.1016\/j.parepi.2022.e00244","volume":"17","author":"L Gujjari","year":"2022","unstructured":"Gujjari L, Kalani H, Pindiprolu SK, et al. Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria. Parasite Epidemiol control. 2022;17:e00244.","journal-title":"Parasite Epidemiol control"},{"issue":"3","key":"4695_CR4","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S2666-5247(24)00016-8","volume":"5","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan P. The 2023 WHO World malaria report. Lancet Microbe. 2024;5(3):e214.","journal-title":"Lancet Microbe"},{"key":"4695_CR5","unstructured":"Organization WH. World malaria report 2023. World Health Organization; 2023."},{"issue":"2","key":"4695_CR6","first-page":"205","volume":"139","author":"AR Anvikar","year":"2014","unstructured":"Anvikar AR, Arora U, Sonal GS, et al. Antimalarial drug policy in India: past, present & future. Indian J Med Res. 2014;139(2):205\u201315.","journal-title":"Indian J Med Res"},{"key":"4695_CR7","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez MJA, del Olmo LMB, Ticona LA et al. Pharmacological potentials of artemisinin and related sesquiterpene lactones: recent advances and trends. Artemisia annua-pharmacology Biotechnol. 2013:75\u201393.","DOI":"10.1007\/978-3-642-41027-7_5"},{"key":"4695_CR8","doi-asserted-by":"crossref","unstructured":"Chaturvedi D. Sesquiterpene lactones: a versatile class of structurally diverse natural products and their semisynthetic analogs as potential antimalarials. Discovery and Development of Therapeutics from Natural Products Against Neglected Tropical Diseases. Elsevier; 2019. pp. 49\u201385.","DOI":"10.1016\/B978-0-12-815723-7.00003-1"},{"key":"4695_CR9","doi-asserted-by":"crossref","unstructured":"Tiwari MK, Chaudhary S. Artemisinin analogues as a novel class of antimalarial agents: recent developments, current scenario and future perspectives. Front Drug Des Discovery. 2022:75\u2013115.","DOI":"10.2174\/9789815036879122110005"},{"issue":"2\u20133","key":"4695_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0163-7258(01)00140-1","volume":"90","author":"GA Balint","year":"2001","unstructured":"Balint GA. Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther. 2001;90(2\u20133):261\u20135.","journal-title":"Pharmacol Ther"},{"key":"4695_CR11","doi-asserted-by":"publisher","first-page":"107658","DOI":"10.1016\/j.pharmthera.2020.107658","volume":"216","author":"N Ma","year":"2020","unstructured":"Ma N, Zhang Z, Liao F, et al. The birth of artemisinin. Pharmacol Ther. 2020;216:107658.","journal-title":"Pharmacol Ther"},{"key":"4695_CR12","doi-asserted-by":"crossref","unstructured":"Liu E, Bai S, Huang Y et al. Studies on the Critical Therapeutic Role of Artemisinin and its Derivatives in Melanoma: a Review of Preclinical Evidence. Curr Treat Options Oncol. 2025:1\u201322.","DOI":"10.1007\/s11864-025-01356-y"},{"key":"4695_CR13","first-page":"1","volume-title":"Antimalarial natural products","author":"DG Kingston","year":"2022","unstructured":"Kingston DG, Cassera MB. Antimalarial natural products. Antimalarial Natural Products: Springer; 2022. pp. 1\u2013106."},{"issue":"9","key":"4695_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/aps.2012.104","volume":"33","author":"Y Li","year":"2012","unstructured":"Li Y. Qinghaosu (artemisinin): chemistry and pharmacology. Acta Pharmacol Sin. 2012;33(9):1141\u20136.","journal-title":"Acta Pharmacol Sin"},{"key":"4695_CR15","doi-asserted-by":"crossref","unstructured":"Pryce J, Taylor M, Fox T et al. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database of Systematic Reviews. 2022;6.","DOI":"10.1002\/14651858.CD006404.pub4"},{"issue":"1","key":"4695_CR16","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/S2666-5247(21)00192-0","volume":"3","author":"W Stone","year":"2022","unstructured":"Stone W, Mahamar A, Sanogo K, et al. Pyronaridine\u2013artesunate or dihydroartemisinin\u2013piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ou\u00e9less\u00e9bougou, Mali: a four-arm, single-blind, phase 2\/3, randomised trial. Lancet Microbe. 2022;3(1):e41\u201351.","journal-title":"Lancet Microbe"},{"issue":"12\/01","key":"4695_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nrmicro2239","volume":"2009","author":"RT Eastman","year":"2009","unstructured":"Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;2009(12\/01):864\u201374.","journal-title":"Nat Rev Microbiol"},{"key":"4695_CR18","doi-asserted-by":"crossref","unstructured":"Wong KH, Yang D, Chen S et al. Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review. Asian J Pharm Sci. 2022;17(4):475\u2013490.","DOI":"10.1016\/j.ajps.2022.04.005"},{"issue":"1","key":"4695_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-8-58","volume":"8","author":"J Gutman","year":"2009","unstructured":"Gutman J, Green M, Durand S, et al. Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. Malar J. 2009;8(1):1\u20138.","journal-title":"Malar J"},{"issue":"10","key":"4695_CR20","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1128\/AAC.00482-15","volume":"59","author":"K Kay","year":"2015","unstructured":"Kay K, Hodel EM, Hastings IM. Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness. Antimicrob Agents Chemother. 2015;59(10):6419\u201327.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4695_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12936-024-04844-y","volume":"23","author":"E Kokori","year":"2024","unstructured":"Kokori E, Olatunji G, Akinboade A, et al. Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts. Malar J. 2024;23(1):25.","journal-title":"Malar J"},{"issue":"1","key":"4695_CR22","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1038\/s41467-023-39914-3","volume":"14","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Gao B, Amaratunga C, et al. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nat Commun. 2023;14(1):4568. 2023\/07\/29.","journal-title":"Nat Commun"},{"key":"4695_CR23","doi-asserted-by":"crossref","unstructured":"van der Pluijm RW, Amaratunga C, Dhorda M et al. Triple Artemisinin-Based Combination Therapies for Malaria \u2013 A New Paradigm? Trends in Parasitology. 2021 2021\/01\/01\/;37(1):15\u201324.","DOI":"10.1016\/j.pt.2020.09.011"},{"key":"4695_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijpddr.2021.05.008","volume":"16","author":"J Zech","year":"2021","unstructured":"Zech J, Dzikowski R, Simantov K, et al. Transdermal delivery of artemisinins for treatment of pre-clinical cerebral malaria. Int J Parasitol Drugs Drug Resist. 2021;16:148\u201354.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"6694","key":"4695_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1126\/science.abq3711","volume":"384","author":"N Feliu","year":"2024","unstructured":"Feliu N, Parak WJ. Developing future nanomedicines. Science. 2024;384(6694):385\u20136.","journal-title":"Science"},{"issue":"4","key":"4695_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1021\/acs.bioconjchem.2c00066","volume":"33","author":"J Han","year":"2022","unstructured":"Han J, Yang W, Li Y, et al. Combining doxorubicin-conjugated polymeric nanoparticles and 5-aminolevulinic acid for enhancing radiotherapy against lung cancer. Bioconjug Chem. 2022;33(4):654\u201365.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"4695_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.carbpol.2013.02.030","volume":"95","author":"K Singh","year":"2013","unstructured":"Singh K, Tiwary A, Rana V. Ethylenediaminediacetic acid bis (carbido amide chitosan): Synthesis and evaluation as solid carrier to fabricate nanoemulsion. Carbohydr Polym. 2013;95(1):303\u201314.","journal-title":"Carbohydr Polym"},{"issue":"21","key":"4695_CR28","doi-asserted-by":"publisher","first-page":"2205606","DOI":"10.1002\/smll.202205606","volume":"19","author":"M Budiarta","year":"2023","unstructured":"Budiarta M, Roy S, Katenkamp T, et al. Overcoming Non-Specific Interactions for Efficient Encapsulation of Doxorubicin in Ferritin Nanocages for Targeted Drug Delivery. Small. 2023;19(21):2205606.","journal-title":"Small"},{"key":"4695_CR29","doi-asserted-by":"crossref","unstructured":"Rana V, Kamboj S, Sharma R et al. Modification of gums: synthesis techniques and pharmaceutical benefits. Handbook of polymers for pharmaceutical technologies: Biodegradable Polym. 2015;3:299\u2013364.","DOI":"10.1002\/9781119041450.ch10"},{"key":"4695_CR30","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.2147\/IJN.S166021","volume":"13","author":"SG Lee","year":"2018","unstructured":"Lee SG, Kim CH, Sung SW, et al. RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells. Int J Nanomed. 2018;13:3263\u201378.","journal-title":"Int J Nanomed"},{"issue":"8","key":"4695_CR31","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1016\/j.apsb.2022.01.005","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhu Y, Wei X, et al. Nanoplateletsomes restrain metastatic tumor formation through decoy and active targeting in a preclinical mouse model. Acta Pharm Sin B. 2022;12(8):3427\u201347.","journal-title":"Acta Pharm Sin B"},{"key":"4695_CR32","doi-asserted-by":"crossref","unstructured":"Song Y, Zhang N, Li Q et al. Biomimetic liposomes hybrid with platelet membranes for targeted therapy of atherosclerosis. Chem Eng J. 2021\/;408:127296.","DOI":"10.1016\/j.cej.2020.127296"},{"issue":"1","key":"4695_CR33","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1038\/s41598-022-06677-8","volume":"12","author":"H Lu","year":"2022","unstructured":"Lu H, Chen T, Wang Y, et al. Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer. Sci Rep. 2022;12(1):2610.","journal-title":"Sci Rep"},{"key":"4695_CR34","doi-asserted-by":"crossref","unstructured":"Huang W, Zhou J, Liang Y et al. Applications of smart responsive nanomaterials in the theranostics of gastrointestinal malignancies: Current status and future perspectives. Coord Chem Rev. 2025;535:216641.","DOI":"10.1016\/j.ccr.2025.216641"},{"key":"4695_CR35","volume-title":"Exploration of nanozymes in viral diagnosis and therapy","year":"2022","unstructured":"Lee J, Liao H, Wang Q, et al. editors. Exploration of nanozymes in viral diagnosis and therapy. Exploration: Wiley Online Library; 2022."},{"issue":"25","key":"4695_CR36","doi-asserted-by":"publisher","first-page":"11863","DOI":"10.1039\/D4NR01454E","volume":"16","author":"G Jia","year":"2024","unstructured":"Jia G, Wang J, Wang H, et al. New insights into red blood cells in tumor precision diagnosis and treatment. Nanoscale. 2024;16(25):11863\u201378.","journal-title":"Nanoscale"},{"issue":"1","key":"4695_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12951-023-02060-5","volume":"21","author":"M Chen","year":"2023","unstructured":"Chen M, Leng Y, He C, et al. Red blood cells: a potential delivery system. J Nanobiotechnol. 2023;21(1):288.","journal-title":"J Nanobiotechnol"},{"issue":"5","key":"4695_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/procel\/pwae001","volume":"15","author":"AT Anastasiadi","year":"2024","unstructured":"Anastasiadi AT, Arvaniti V-Z, Hudson KE, et al. Exploring unconventional attributes of red blood cells and their potential applications in biomedicine. Protein Cell. 2024;15(5):315\u201330.","journal-title":"Protein Cell"},{"issue":"6","key":"4695_CR39","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1021\/acsnano.2c11965","volume":"17","author":"PHD Nguyen","year":"2023","unstructured":"Nguyen PHD, Jayasinghe MK, Le AH, et al. Advances in drug delivery systems based on red blood cells and their membrane-derived nanoparticles. ACS Nano. 2023;17(6):5187\u2013210.","journal-title":"ACS Nano"},{"issue":"3","key":"4695_CR40","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1021\/acsnano.1c11374","volume":"16","author":"LT Ferguson","year":"2022","unstructured":"Ferguson LT, Hood ED, Shuvaeva T, et al. Dual affinity to RBCs and target cells (DART) enhances both organ-and cell type-targeting of intravascular nanocarriers. ACS Nano. 2022;16(3):4666\u201383.","journal-title":"ACS Nano"},{"issue":"11","key":"4695_CR41","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s11095-022-03328-5","volume":"39","author":"E Zhang","year":"2022","unstructured":"Zhang E, Phan P, Algarni HA, et al. Red blood cell inspired strategies for drug delivery: emerging concepts and new advances. Pharm Res. 2022;39(11):2673\u201398.","journal-title":"Pharm Res"},{"issue":"1","key":"4695_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1128\/AAC.39.1.180","volume":"39","author":"M Owais","year":"1995","unstructured":"Owais M, Varshney GC, Choudhury A, et al. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice. Antimicrob Agents Chemother. 1995;39(1):180\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"4695_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4695_CR44","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2174\/09298673113206660292","volume":"21","author":"P Urban","year":"2014","unstructured":"Urban P, Fernandez-Busquets X. Nanomedicine against malaria. Curr Med Chem. 2014;21(5):605\u201329.","journal-title":"Curr Med Chem"},{"issue":"7\u20139","key":"4695_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ejcb.2015.05.007","volume":"94","author":"S Baumeister","year":"2015","unstructured":"Baumeister S, Gangopadhyay P, Repnik U, et al. Novel insights into red blood cell physiology using parasites as tools. Eur J Cell Biol. 2015;94(7\u20139):332\u20139.","journal-title":"Eur J Cell Biol"},{"key":"4695_CR46","doi-asserted-by":"publisher","first-page":"876282","DOI":"10.3389\/fphar.2022.876282","volume":"13","author":"B Hanboonkunupakarn","year":"2022","unstructured":"Hanboonkunupakarn B, Tarning J, Pukrittayakamee S, et al. Artemisinin resistance and malaria elimination: Where are we now? Front Pharmacol. 2022;13:876282.","journal-title":"Front Pharmacol"},{"issue":"11","key":"4695_CR47","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3109\/10715762.2010.498475","volume":"44","author":"R Sen","year":"2010","unstructured":"Sen R, Saha P, Sarkar A, et al. Iron enhances generation of free radicals by Artemisinin causing a caspase-independent, apoptotic death in Leishmania donovani promastigotes. Free Radic Res. 2010;44(11):1289\u201395.","journal-title":"Free Radic Res"},{"key":"4695_CR48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jgar.2021.09.001","volume":"27","author":"N Noreen","year":"2021","unstructured":"Noreen N, Ullah A, Salman SM, et al. New insights into the spread of resistance to artemisinin and its analogues. J Glob Antimicrob Resist. 2021;27:142\u20139.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"4695_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s42003-022-03215-0","volume":"5","author":"L Zhu","year":"2022","unstructured":"Zhu L, van der Pluijm RW, Kucharski M, et al. Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Commun Biol. 2022;5(1):274. 2022\/03\/28.","journal-title":"Commun Biology"},{"issue":"12","key":"4695_CR50","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.pt.2023.09.011","volume":"39","author":"K Pandit","year":"2023","unstructured":"Pandit K, Surolia N, Bhattacharjee S, et al. The many paths to artemisinin resistance in Plasmodium falciparum. Trends Parasitol. 2023;39(12):1060\u201373.","journal-title":"Trends Parasitol"},{"issue":"6","key":"4695_CR51","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.chom.2017.11.005","volume":"22","author":"M Zhang","year":"2017","unstructured":"Zhang M, Gallego-Delgado J, Fernandez-Arias C, et al. Inhibiting the Plasmodium eIF2alpha Kinase PK4 Prevents Artemisinin-Induced Latency. Cell Host Microbe. 2017;22(6):766\u201376. e4.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"4695_CR52","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41467-020-20805-w","volume":"12","author":"S Mok","year":"2021","unstructured":"Mok S, Stokes BH, Gnadig NF, et al. Artemisinin-resistant K13 mutations rewire Plasmodium falciparum\u2019s intra-erythrocytic metabolic program to enhance survival. Nat Commun. 2021;12(1):530.","journal-title":"Nat Commun"},{"key":"4695_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.coph.2018.06.003","volume":"42","author":"N Suresh","year":"2018","unstructured":"Suresh N, Haldar K. Mechanisms of artemisinin resistance in Plasmodium falciparum malaria. Curr Opin Pharmacol. 2018;42:46\u201354.","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"4695_CR54","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1128\/AAC.00287-13","volume":"57","author":"NJ White","year":"2013","unstructured":"White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother. 2013;57(12):5792\u2013807.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4695_CR55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pt.2007.11.008","volume":"24","author":"KI Barnes","year":"2008","unstructured":"Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 2008;24(3):127\u201334.","journal-title":"Trends Parasitol"},{"issue":"16","key":"4695_CR56","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1016\/j.bmc.2015.04.017","volume":"23","author":"R Oliveira","year":"2015","unstructured":"Oliveira R, Miranda D, Magalh\u00e3es J, et al. From hybrid compounds to targeted drug delivery in antimalarial therapy. Bioorg Med Chem. 2015;23(16):5120\u201330.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"4695_CR57","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3390\/molecules22122268","volume":"22","author":"X Nqoro","year":"2017","unstructured":"Nqoro X, Tobeka N, Aderibigbe BA. Quinoline-based hybrid compounds with antimalarial activity. Molecules. 2017;22(12):2268.","journal-title":"Molecules"},{"issue":"25","key":"4695_CR58","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.2174\/138161209789058183","volume":"15","author":"J Walsh","year":"2009","unstructured":"Walsh J, Bell A. Hybrid drugs for malaria. Curr Pharm Design. 2009;15(25):2970\u201385.","journal-title":"Curr Pharm Design"},{"issue":"4","key":"4695_CR59","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/med.20086","volume":"27","author":"L Juillerat-Jeanneret","year":"2007","unstructured":"Juillerat-Jeanneret L, Schmitt F. Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail. Med Res Rev. 2007;27(4):574\u201390.","journal-title":"Med Res Rev"},{"key":"4695_CR60","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1590\/0001-3765201820170830","volume":"90","author":"L Pinheiro","year":"2018","unstructured":"Pinheiro L, Feitosa LM, SILVEIRA FF, et al. Current antimalarial therapies and advances in the development of semi-synthetic artemisinin derivatives. An Acad Bras Cienc. 2018;90:1251\u201371.","journal-title":"An Acad Bras Cienc"},{"issue":"3","key":"4695_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-019-1337-8","volume":"20","author":"S Talegaonkar","year":"2019","unstructured":"Talegaonkar S, Bhattacharyya A. Potential of lipid nanoparticles (SLNs and NLCs) in enhancing oral bioavailability of drugs with poor intestinal permeability. AAPS PharmSciTech. 2019;20(3):1\u201315.","journal-title":"AAPS PharmSciTech"},{"key":"4695_CR62","doi-asserted-by":"publisher","first-page":"105736","DOI":"10.1016\/j.yrtph.2024.105736","volume":"154","author":"P Hewitt","year":"2024","unstructured":"Hewitt P, Hartmann A, Tornesi B, et al. Importance of tailored non-clinical safety testing of novel antimalarial drugs: Industry best-practice. Regul Toxicol Pharmacol. 2024;154:105736.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"4695_CR63","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/cid\/cis958","volume":"56","author":"D Das","year":"2013","unstructured":"Das D, Tripura R, Phyo AP, et al. Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis. 2013;56(5):e48\u201358.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4695_CR64","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1086\/657402","volume":"51","author":"D Bethell","year":"2010","unstructured":"Bethell D, Se Y, Lon C, et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis. 2010;51(12):e105\u201314.","journal-title":"Clin Infect Dis"},{"key":"4695_CR65","doi-asserted-by":"crossref","unstructured":"Prabhu P, Suryavanshi S, Pathak S et al. Artemether\u2ffflumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency. Int J Pharm. 2016;511(1):473\u201387.","DOI":"10.1016\/j.ijpharm.2016.07.021"},{"key":"4695_CR66","doi-asserted-by":"crossref","unstructured":"Bhandari S, Rana V, Tiwary AK. Antimalarial Solid self-emulsifying System for Oral use: In Vitro Investigation. Therapeutic Delivery. 2017;8(4):201\u201313.","DOI":"10.4155\/tde-2016-0092"},{"issue":"1","key":"4695_CR67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.carbpol.2013.02.030","volume":"95","author":"K Singh","year":"2013","unstructured":"Singh K, Tiwary AK, Rana V. Ethylenediaminediacetic acid bis(carbido amide chitosan): synthesis and evaluation as solid carrier to fabricate nanoemulsion. Carbohydr Polym. 2013;95(1):303\u201314.","journal-title":"Carbohydr Polym"},{"key":"4695_CR68","doi-asserted-by":"crossref","unstructured":"Zhu Y, Liu Y, Pang Z. Chitosan in drug delivery applications. Natural Polysaccharides in Drug Delivery and Biomedical Applications. Elsevier; 2019. pp. 101\u201319.","DOI":"10.1016\/B978-0-12-817055-7.00004-2"},{"key":"4695_CR69","doi-asserted-by":"crossref","unstructured":"Zhu Y, Pang Z. Hyaluronic acid in drug delivery applications. Natural Polysaccharides in Drug Delivery and Biomedical Applications. Elsevier; 2019. pp. 307\u201325.","DOI":"10.1016\/B978-0-12-817055-7.00013-3"},{"key":"4695_CR70","doi-asserted-by":"crossref","unstructured":"Miatmoko A, Nurjannah I, Nehru NF et al. Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes. Sci Rep. 2021;11(1):12420.","DOI":"10.1038\/s41598-021-91866-0"},{"issue":"1","key":"4695_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/08982104.2017.1410173","volume":"29","author":"K Shakeel","year":"2019","unstructured":"Shakeel K, Raisuddin S, Ali S, et al. Development and in vitro\/in vivo evaluation of artemether and lumefantrine co-loaded nanoliposomes for parenteral delivery. J Liposome Res. 2019;29(1):35\u201343.","journal-title":"J Liposome Res"},{"issue":"1\u20132","key":"4695_CR72","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijpharm.2014.03.036","volume":"466","author":"P Dwivedi","year":"2014","unstructured":"Dwivedi P, Khatik R, Khandelwal K, et al. Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm. 2014;466(1\u20132):321\u20137.","journal-title":"Int J Pharm"},{"issue":"3","key":"4695_CR73","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4269\/ajtmh.21-1115","volume":"106","author":"M Nain","year":"2022","unstructured":"Nain M, Mohan M, Sharma A. Effects of host genetic polymorphisms on the efficacy of the radical cure malaria drug primaquine. Am J Trop Med Hyg. 2022;106(3):764.","journal-title":"Am J Trop Med Hyg"},{"key":"4695_CR74","doi-asserted-by":"crossref","unstructured":"Patel DJ, Chaudhary S, Chaudhary AB, et al. Dendrimers-Based Drug Delivery in Tuberculosis. Tubercular Drug Delivery Systems: Advances in Treatment of Infectious Diseases. Springer; 2023. pp. 123\u201343.","DOI":"10.1007\/978-3-031-14100-3_7"},{"issue":"1","key":"4695_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"X Li","year":"2024","unstructured":"Li X, Peng X, Zoulikha M, et al. Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct Target Therapy. 2024;9(1):1.","journal-title":"Signal Transduct Target Therapy"},{"key":"4695_CR76","doi-asserted-by":"crossref","unstructured":"Dauda K, Busari Z, Morenikeji O, et al. Poly(D,L-lactic-co-glycolic acid)-based artesunate nanoparticles: formulation, antimalarial and toxicity assessments. J Zhejiang Univ Sci B. 2017;18(11):977\u201385.","DOI":"10.1631\/jzus.B1600389"},{"issue":"1","key":"4695_CR77","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/10717544.2014.905883","volume":"23","author":"D Parashar","year":"2016","unstructured":"Parashar D, NP A. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity. Drug Delivery. 2016;23(1):123\u20139.","journal-title":"Drug Delivery"},{"issue":"1","key":"4695_CR78","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1166\/jbn.2023.3492","volume":"19","author":"H Xue","year":"2023","unstructured":"Xue H, Jin X, Song R, et al. Pharmacokinetic Profiling of Prepared Artemisinin-Loaded Poly (lactic co-glycolic acid) Nanoparticles in Mice Infected with Artemisinin-Sensitive and-Resistant Plasmodium berghei K173 Using by HPLC-MS\/MS Assay. J Biomed Nanotechnol. 2023;19(1):87\u201397.","journal-title":"J Biomed Nanotechnol"},{"key":"4695_CR79","doi-asserted-by":"crossref","unstructured":"Potharaju S, Mutyam SK, Liu M et al. Improving solubility and oral bioavailability of a novel antimalarial prodrug: comparing spray-dried dispersions with self-emulsifying drug delivery systems. Pharm Dev Technol. 2020;25(5):625\u201339.","DOI":"10.1080\/10837450.2020.1725893"},{"issue":"2","key":"4695_CR80","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1872208313666181204095314","volume":"13","author":"CE Umeyor","year":"2019","unstructured":"Umeyor CE, Obachie O, Chukwuka R, et al. Development Insights of Surface Modified Lipid Nanoemulsions of Dihydroartemisinin for Malaria Chemotherapy: Characterization, and in vivo Antimalarial Evaluation. Recent Pat Biotechnol. 2019;13(2):149\u201365.","journal-title":"Recent Pat Biotechnol"},{"issue":"9","key":"4695_CR81","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S1473-3099(23)00209-8","volume":"23","author":"B Ogutu","year":"2023","unstructured":"Ogutu B, Yeka A, Kusemererwa S, et al. Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial. Lancet Infect Dis. 2023;23(9):1051\u201361.","journal-title":"Lancet Infect Dis"},{"key":"4695_CR82","doi-asserted-by":"crossref","unstructured":"Torkashvand H, Dehdast SA, Nateghpour M et al. Antimalarial nano-drug delivery system based on graphene quantum dot on Plasmodium falciparum: Preparation, characterization, toxicological evaluation. Diam Relat Mater. 2023;132:109670.","DOI":"10.1016\/j.diamond.2022.109670"},{"issue":"1s","key":"4695_CR83","doi-asserted-by":"publisher","first-page":"s225","DOI":"10.18433\/jpps30117","volume":"21","author":"J Emami","year":"2018","unstructured":"Emami J, Yousefian H, Sadeghi H. Targeted nanostructured lipid carrier for brain delivery of artemisinin: design, preparation, characterization, optimization and cell toxicity. J Pharm Pharm Sci. 2018;21(1s):s225\u201341.","journal-title":"J Pharm Pharm Sci"},{"issue":"4\u20135","key":"4695_CR84","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.addr.2009.11.024","volume":"62","author":"NS Santos-Magalh\u00e3es","year":"2010","unstructured":"Santos-Magalh\u00e3es NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev. 2010;62(4\u20135):560\u201375.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"4695_CR85","first-page":"414","volume":"6","author":"M Thakkar","year":"2016","unstructured":"Thakkar M. Combating malaria with nanotechnology-based targeted and combinatorial drug delivery strategies. Drug delivery translational Res. 2016;6(4):414\u201325.","journal-title":"Drug delivery translational Res"},{"key":"4695_CR86","doi-asserted-by":"crossref","unstructured":"Amos Y, Rubaka C, Sauli E et al. Nanotechnology-based delivery strategies for drugs and vaccines targeting blood stage malaria: A systematic review. Nanomed Nanotechnol Biol Med. 2025:102869.","DOI":"10.1016\/j.nano.2025.102869"},{"key":"4695_CR87","doi-asserted-by":"crossref","unstructured":"Gupta S, Umeyor CE, Patravale VB. Role of nanotechnology against malaria: current perspectives and strategies. Nanomedicines for the Prevention and Treatment of Infectious Diseases. 2023:197\u2013238.","DOI":"10.1007\/978-3-031-39020-3_7"},{"key":"4695_CR88","doi-asserted-by":"crossref","unstructured":"Boulet C, Doerig CD, Carvalho TG. Manipulating eryptosis of human red blood cells: a novel antimalarial strategy? Frontiers in cellular and infection microbiology. 2018;8:419.","DOI":"10.3389\/fcimb.2018.00419"},{"key":"4695_CR89","doi-asserted-by":"publisher","first-page":"816574","DOI":"10.3389\/fcimb.2022.816574","volume":"12","author":"J Molina-Franky","year":"2022","unstructured":"Molina-Franky J, Patarroyo ME, Kalkum M, et al. The Cellular and Molecular Interaction Between Erythrocytes and Plasmodium falciparum Merozoites. Front Cell Infect Microbiol. 2022;12:816574.","journal-title":"Front Cell Infect Microbiol"},{"key":"4695_CR90","doi-asserted-by":"crossref","unstructured":"Maguire PA, Prudhomme J, Sherman IW. Alterations in erythrocyte membrane phospholipid organization due to the intracellular growth of the human malaria parasite, Plasmodium falciparum. Parasitology. 1991;102(Pt 2):179\u201386.","DOI":"10.1017\/S0031182000062466"},{"issue":"1","key":"4695_CR91","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12916-017-0945-y","volume":"15","author":"E Shabani","year":"2017","unstructured":"Shabani E, Hanisch B, Opoka RO, et al. Plasmodium falciparum EPCR-binding PfEMP1 expression increases with malaria disease severity and is elevated in retinopathy negative cerebral malaria. BMC Med. 2017;15(1):183. 2017\/10\/13.","journal-title":"BMC Med"},{"issue":"4","key":"4695_CR92","doi-asserted-by":"publisher","first-page":"e1009509","DOI":"10.1371\/journal.pcbi.1009509","volume":"18","author":"J Jager","year":"2022","unstructured":"Jager J, Patra P, Sanchez CP, et al. A particle-based computational model to analyse remodelling of the red blood cell cytoskeleton during malaria infections. PLoS Comput Biol. 2022;18(4):e1009509.","journal-title":"PLoS Comput Biol"},{"issue":"11","key":"4695_CR93","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood-2017-11-814665","volume":"131","author":"S Bhattacharjee","year":"2018","unstructured":"Bhattacharjee S, Coppens I, Mbengue A, et al. Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood. 2018;131(11):1234\u201347.","journal-title":"Blood"},{"issue":"1","key":"4695_CR94","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/imr.12807","volume":"293","author":"AR Jensen","year":"2020","unstructured":"Jensen AR, Adams Y, Hviid L. Cerebral Plasmodium falciparum malaria: The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. Immunol Rev. 2020;293(1):230\u201352.","journal-title":"Immunol Rev"},{"issue":"1","key":"4695_CR95","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12951-022-01709-x","volume":"21","author":"Z He","year":"2023","unstructured":"He Z, Yu C, Pan Z, et al. Erythrocyte membrane with CLIPPKF as biomimetic nanodecoy traps merozoites and attaches to infected red blood cells to prevent Plasmodium infection. J Nanobiotechnol. 2023;21(1):15.","journal-title":"J Nanobiotechnol"},{"key":"4695_CR96","doi-asserted-by":"crossref","unstructured":"Wang R, Yang J, Qiang J et al. Glucose-functionalized redox-responsive dihydroartemisinin prodrug nanosystem for targeted malaria therapy. Int J Pharmaceutics: X. 2025;10:100370.","DOI":"10.1016\/j.ijpx.2025.100370"},{"issue":"1","key":"4695_CR97","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/1556-276X-6-620","volume":"6","author":"P Urban","year":"2011","unstructured":"Urban P, Estelrich J, Adeva A, et al. Study of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovectors. Nanoscale Res Lett. 2011;6(1):620.","journal-title":"Nanoscale Res Lett"},{"key":"4695_CR98","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2016.09.006","volume":"241","author":"E Moles","year":"2016","unstructured":"Moles E, Moll K, Ch\u2019ng J-H, et al. Development of drug-loaded immunoliposomes for the selective targeting and elimination of rosetting Plasmodium falciparum-infected red blood cells. J Controlled Release. 2016;241:57\u201367.","journal-title":"J Controlled Release"},{"issue":"7","key":"4695_CR99","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/pharmaceutics11070341","volume":"11","author":"A Biosca","year":"2019","unstructured":"Biosca A, Dirscherl L, Moles E, et al. An immunoPEGliposome for targeted antimalarial combination therapy at the nanoscale. Pharmaceutics. 2019;11(7):341.","journal-title":"Pharmaceutics"},{"issue":"5","key":"4695_CR100","doi-asserted-by":"publisher","first-page":"e0206521","DOI":"10.1128\/aac.02065-21","volume":"66","author":"Y Du","year":"2022","unstructured":"Du Y, Giannangelo C, He W, et al. Dimeric Artesunate Glycerophosphocholine Conjugate Nano-Assemblies as Slow-Release Antimalarials to Overcome Kelch 13 Mutant Artemisinin Resistance. Antimicrob Agents Chemother. 2022;66(5):e0206521.","journal-title":"Antimicrob Agents Chemother"},{"key":"4695_CR101","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2013.12.032","volume":"177","author":"P Urban","year":"2014","unstructured":"Urban P, Valle-Delgado JJ, Mauro N, et al. Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium. J Control Release. 2014;177:84\u201395.","journal-title":"J Control Release"},{"issue":"27","key":"4695_CR102","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.1016\/j.biomaterials.2014.05.061","volume":"35","author":"J Movellan","year":"2014","unstructured":"Movellan J, Urban P, Moles E, et al. Amphiphilic dendritic derivatives as nanocarriers for the targeted delivery of antimalarial drugs. Biomaterials. 2014;35(27):7940\u201350.","journal-title":"Biomaterials"},{"key":"4695_CR103","doi-asserted-by":"publisher","first-page":"121665","DOI":"10.1016\/j.ijpharm.2022.121665","volume":"618","author":"H Zuo","year":"2022","unstructured":"Zuo H, Qiang J, Wang Y, et al. Design of red blood cell membrane-cloaked dihydroartemisinin nanoparticles with enhanced antimalarial efficacy. Int J Pharm. 2022;618:121665.","journal-title":"Int J Pharm"},{"issue":"1","key":"4695_CR104","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1021\/acsami.0c20070","volume":"13","author":"X Wang","year":"2020","unstructured":"Wang X, Xie Y, Jiang N, et al. Enhanced antimalarial efficacy obtained by targeted delivery of artemisinin in heparin-coated magnetic hollow mesoporous nanoparticles. ACS Appl Mater Interfaces. 2020;13(1):287\u201397.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"4695_CR105","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1021\/acsami.0c20070","volume":"13","author":"X Wang","year":"2021","unstructured":"Wang X, Xie Y, Jiang N, et al. Enhanced Antimalarial Efficacy Obtained by Targeted Delivery of Artemisinin in Heparin-Coated Magnetic Hollow Mesoporous Nanoparticles. ACS Appl Mater Interfaces. 2021;13(1):287\u201397.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"21","key":"4695_CR106","first-page":"2809","volume":"11","author":"AA Sidhaye","year":"2016","unstructured":"Sidhaye AA, Bhuran KC, Zambare S, et al. Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes. Nanomed (Lond). 2016;11(21):2809\u201328.","journal-title":"Nanomed (Lond)"},{"issue":"39","key":"4695_CR107","doi-asserted-by":"publisher","first-page":"43380","DOI":"10.1021\/acsami.0c09075","volume":"12","author":"S Varela-Aramburu","year":"2020","unstructured":"Varela-Aramburu S, Ghosh C, Goerdeler F, et al. Targeting and inhibiting Plasmodium falciparum using ultra-small gold nanoparticles. ACS Appl Mater Interfaces. 2020;12(39):43380\u20137.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"39","key":"4695_CR108","doi-asserted-by":"publisher","first-page":"43380","DOI":"10.1021\/acsami.0c09075","volume":"12","author":"S Varela-Aramburu","year":"2020","unstructured":"Varela-Aramburu S, Ghosh C, Goerdeler F, et al. Targeting and Inhibiting Plasmodium falciparum Using Ultra-small Gold Nanoparticles. ACS Appl Mater Interfaces. 2020;12(39):43380\u20137.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4695_CR109","doi-asserted-by":"publisher","first-page":"102470","DOI":"10.1016\/j.apmt.2024.102470","volume":"41","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Jiang N, Li Q, et al. Improved anti-malarial parasite efficacy with heparin-artemisinin nanoemulsions. Appl Mater Today. 2024;41:102470.","journal-title":"Appl Mater Today"},{"key":"4695_CR110","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jconrel.2023.11.057","volume":"365","author":"C Yang","year":"2024","unstructured":"Yang C, Xue Y, Duan Y, et al. Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications. J Controlled Release. 2024;365:1089\u2013123.","journal-title":"J Controlled Release"},{"key":"4695_CR111","doi-asserted-by":"crossref","unstructured":"Erana-Perez Z, Igartua M, Santos-Vizcaino E et al. Genetically engineered loaded extracellular vesicles for drug delivery. Trends Pharmacol Sci. 2024.","DOI":"10.1016\/j.tips.2024.02.006"},{"key":"4695_CR112","doi-asserted-by":"publisher","first-page":"119627","DOI":"10.1016\/j.ijpharm.2020.119627","volume":"587","author":"LN Borgheti-Cardoso","year":"2020","unstructured":"Borgheti-Cardoso LN, Kooijmans SAA, Chamorro LG, et al. Extracellular vesicles derived from Plasmodium-infected and non-infected red blood cells as targeted drug delivery vehicles. Int J Pharm. 2020;587:119627.","journal-title":"Int J Pharm"},{"key":"4695_CR113","doi-asserted-by":"crossref","unstructured":"de Vlieger JS, Crommelin DJ, Tyner K, et al. Report of the AAPS guidance forum on the FDA draft guidance for industry:Drug products, including biological products, that contain nanomaterials. Springer; 2019.","DOI":"10.1208\/s12248-019-0329-7"},{"issue":"17","key":"4695_CR114","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1039\/D0BM00558D","volume":"8","author":"R Foulkes","year":"2020","unstructured":"Foulkes R, Man E, Thind J, et al. The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomaterials Sci. 2020;8(17):4653\u201364.","journal-title":"Biomaterials Sci"},{"key":"4695_CR115","doi-asserted-by":"crossref","unstructured":"Kumar S, Ali J, Baboota S. Regulatory requirement for the approval of novel, nanotechnology-based biological products. Regulatory Affairs in the Pharmaceutical Industry: Elsevier; 2022. pp. 31\u201345.","DOI":"10.1016\/B978-0-12-822211-9.00009-5"},{"key":"4695_CR116","doi-asserted-by":"crossref","unstructured":"\u00c7etinta\u015f HC, Tonbul H, \u015eahin A et al. Regulatory guidelines of the US food and drug administration and the european medicines agency for actively targeted nanomedicines. Drug Delivery Target Nanopart. 2021:725\u201341.","DOI":"10.1201\/9781003164739-27"},{"issue":"1","key":"4695_CR117","first-page":"5723","volume":"15","author":"B Medhi","year":"2022","unstructured":"Medhi B. Guidelines for nanopharmaceutical products for regulatory approval. Int J Pharm Sci Nanatechnol (IJPSN). 2022;15(1):5723\u20135.","journal-title":"Int J Pharm Sci Nanatechnol (IJPSN)"},{"issue":"3","key":"4695_CR118","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/2213476X06666191129094236","volume":"7","author":"R Malik","year":"2020","unstructured":"Malik R, Patil S, Nanotechnology. Regulatory outlook on nanomaterials and nanomedicines in United States, Europe and India. Applied Clinical Research. Clin Trials Regul Affairs. 2020;7(3):225\u201336.","journal-title":"Clin Trials Regul Affairs"},{"issue":"3","key":"4695_CR119","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.bbrc.2015.08.023","volume":"468","author":"V Sainz","year":"2015","unstructured":"Sainz V, Conniot J, Matos AI, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468(3):504\u201310.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4695_CR120","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s11671-025-04311-w","volume":"2025\/11\/05","author":"TF Egza","year":"2025","unstructured":"Egza TF, Kebede EM, Perumal RD. Advancing malaria treatment with magnetic and mesoporous silica nanoparticles loaded with sulfadoxine-pyrimethamine: a review. Discover Nano. 2025:199.","journal-title":"Discover Nano"},{"key":"4695_CR121","doi-asserted-by":"crossref","unstructured":"Bosetti R, Jones SL. Cost\u2013Effectiveness of Nanomedicine: Estimating the Real Size of Nano-Costs. Nanomedicine. 2019 2019\/06\/01;14(11):1367\u201370.","DOI":"10.2217\/nnm-2019-0130"},{"issue":"15","key":"4695_CR122","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2174\/1389450122666210204203132","volume":"22","author":"E Bhargav","year":"2021","unstructured":"Bhargav E, Koteshwara K. A Review on Development and Characterization of a Cost-effective Targeted Quality-driven Antimalarial Product with an Emphasis on Phytosomes. Curr Drug Targets. 2021;22(15):1772\u201388.","journal-title":"Curr Drug Targets"},{"key":"4695_CR123","doi-asserted-by":"crossref","unstructured":"Deshmukh R, Dewangan B, Harwansh RK et al. Current Trends in Nanotechnology-based Drug Delivery Systems for the Diagnosis and Treatment of Malaria: A Review. Curr Drug Deliv. 2025.","DOI":"10.2174\/0115672018291253240115012327"},{"issue":"6","key":"4695_CR124","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1080\/02652048.2024.2376116","volume":"41","author":"H Hameed","year":"2024","unstructured":"Hameed H, Khan MA, Paiva-Santos AC, et al. Liposomes like advanced drug carriers: from fundamentals to pharmaceutical applications. J Microencapsul. 2024;41(6):456\u201378.","journal-title":"J Microencapsul"},{"issue":"46","key":"4695_CR125","doi-asserted-by":"publisher","first-page":"e04197","DOI":"10.1002\/advs.202504197","volume":"12","author":"Z Tu","year":"2025","unstructured":"Tu Z, Lin J, Li Z, et al. Tackling Allergic Airway Inflammation with Organic Sheet-Like Nanoplatforms by Targeted Elimination of Epithelial Small Extracellular Vesicles. Adv Sci. 2025;12(46):e04197.","journal-title":"Adv Sci"},{"issue":"1","key":"4695_CR126","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1038\/s41467-025-61236-9","volume":"16","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Xu C, Li Z, et al. Nanostructured organic sheets sequestering small extracellular vesicles and reactive species to protect against radiation-induced mucositis. Nat Commun. 2025;16(1):6120.","journal-title":"Nat Commun"},{"issue":"39","key":"4695_CR127","doi-asserted-by":"publisher","first-page":"2205663","DOI":"10.1002\/adfm.202205663","volume":"32","author":"Z Tu","year":"2022","unstructured":"Tu Z, Zhu Y, Xiao Y, et al. Scavenging tumor-derived small extracellular vesicles by functionalized 2D materials to inhibit tumor regrowth and metastasis following radiotherapy. Adv Funct Mater. 2022;32(39):2205663.","journal-title":"Adv Funct Mater"},{"issue":"11","key":"4695_CR128","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/pharmaceutics11110567","volume":"11","author":"J-M delMoral-Sanchez","year":"2019","unstructured":"delMoral-Sanchez J-M, Gonzalez-Alvarez I, Gonzalez-Alvarez M, et al. Classification of WHO essential oral medicines for children applying a provisional pediatric biopharmaceutics classification system. Pharmaceutics. 2019;11(11):567.","journal-title":"Pharmaceutics"},{"key":"4695_CR129","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, et al. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J"},{"issue":"1","key":"4695_CR130","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/jps.22249","volume":"100","author":"S Strauch","year":"2011","unstructured":"Strauch S, Jantratid E, Dressman J, et al. Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride. J Pharm Sci. 2011;100(1):11\u201321.","journal-title":"J Pharm Sci"},{"issue":"12","key":"4695_CR131","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1002\/jps.23312","volume":"101","author":"A Nair","year":"2012","unstructured":"Nair A, Abrahamsson B, Barends DM, et al. Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride. J Pharm Sci. 2012;101(12):4390\u2013401.","journal-title":"J Pharm Sci"},{"issue":"1","key":"4695_CR132","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12936-020-03553-6","volume":"20","author":"TA Anyorigiya","year":"2021","unstructured":"Anyorigiya TA, Castel S, Mauff K, et al. Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria. Malar J. 2021;20(1):18.","journal-title":"Malar J"},{"key":"4695_CR133","unstructured":"Organization WH. The Selection and Use of Essential Medicine. Geneva, Switzerland 2005."},{"issue":"12","key":"4695_CR134","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1128\/AAC.05067-11","volume":"55","author":"MJ Rijken","year":"2011","unstructured":"Rijken MJ, McGready R, Phyo AP, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2011;55(12):5500\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4695_CR135","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1473-3099(16)30459-5","volume":"17","author":"Q Bassat","year":"2017","unstructured":"Bassat Q, Men\u00e9ndez C. Dihydroartemisinin-piperaquine: if it works for control, can we use it for elimination? Lancet Infect Dis. 2017;17(2):121\u20132.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4695_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-020-03209-5","volume":"19","author":"S Belew","year":"2020","unstructured":"Belew S, Suleman S, Duguma M, et al. Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether\/lumefantrine tablets. Malar J. 2020;19(1):1\u201312.","journal-title":"Malar J"},{"issue":"11","key":"4695_CR137","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/jphp.12795","volume":"69","author":"S Bhandari","year":"2017","unstructured":"Bhandari S, Bhandari V, Sood J, et al. Improved pharmacokinetic and pharmacodynamic attributes of artemether\u2013lumefantrine-loaded solid SMEDDS for oral administration. J Pharm Pharmacol. 2017;69(11):1437\u201346.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"4695_CR138","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s11671-023-03955-w","volume":"19","author":"S Nemati","year":"2024","unstructured":"Nemati S, Mottaghi M, Karami P, et al. Development of solid lipid nanoparticles-loaded drugs in parasitic diseases. Discover Nano. 2024;19(1):7.","journal-title":"Discover Nano"},{"issue":"2","key":"4695_CR139","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jconrel.2011.01.001","volume":"151","author":"P Urb\u00e1n","year":"2011","unstructured":"Urb\u00e1n P, Estelrich J, Cort\u00e9s A, et al. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro. J Controlled Release. 2011;151(2):202\u201311.","journal-title":"J Controlled Release"},{"key":"4695_CR140","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jconrel.2015.05.284","volume":"210","author":"E Moles","year":"2015","unstructured":"Moles E, Urb\u00e1n P, Jim\u00e9nez-D\u00edaz MB, et al. Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic\/prophylactic antimalarial strategy. J Controlled Release. 2015;210:217\u201329.","journal-title":"J Controlled Release"},{"key":"4695_CR141","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.biomaterials.2017.08.020","volume":"145","author":"E Moles","year":"2017","unstructured":"Moles E, Galiano S, Gomes A, et al. ImmunoPEGliposomes for the targeted delivery of novel lipophilic drugs to red blood cells in a falciparum malaria murine model. Biomaterials. 2017;145:178\u201391.","journal-title":"Biomaterials"},{"key":"4695_CR142","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jconrel.2021.01.028","volume":"331","author":"A Biosca","year":"2021","unstructured":"Biosca A, Cabanach P, Abdulkarim M, et al. Zwitterionic self-assembled nanoparticles as carriers for Plasmodium targeting in malaria oral treatment. J Controlled Release. 2021;331:364\u201375.","journal-title":"J Controlled Release"},{"key":"4695_CR143","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2013.12.032","volume":"177","author":"P Urb\u00e1n","year":"2014","unstructured":"Urb\u00e1n P, Valle-Delgado JJ, Mauro N, et al. Use of poly (amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium. J Controlled Release. 2014;177:84\u201395.","journal-title":"J Controlled Release"},{"key":"4695_CR144","doi-asserted-by":"crossref","unstructured":"Borgheti-Cardoso LN, Kooijmans SAA, Chamorro LG et al. Extracellular vesicles derived from Plasmodium-infected and non-infected red blood cells as targeted drug delivery vehicles. Int J Pharm. 2020;587:119627.","DOI":"10.1016\/j.ijpharm.2020.119627"},{"issue":"21","key":"4695_CR145","first-page":"2809","volume":"11","author":"AA Sidhaye","year":"2016","unstructured":"Sidhaye AA, Bhuran KC, Zambare S, et al. Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes. Nanomedicine. 2016;11(21):2809\u201328.","journal-title":"Nanomedicine"},{"key":"4695_CR146","unstructured":"Zhao Yongdan WY, Lu, Xiaolin. Wang Qian, inventor; Shanxi Medical University, assignee. Nanocarriers acting on plasmodium in erythrophase, preparation and preparation method thereof. China 2022."},{"key":"4695_CR147","unstructured":"Niles ARSFJRAC. inventor; Massachusetts Institute of Technology, assignee. Delivery of materials to anucleate cells. US2022 2022-03-08."},{"key":"4695_CR148","unstructured":"Liang Jianming HZ. Li Zengfeng, inventor; Guangzhou University of Traditional Chinese Medicine, assignee. Artemether liposomes, erythrocyte membrane-encapsulated liposomes, targeting peptide-modified biomimetic liposomes, and their preparation methods and applications for treating malaria. China2021."},{"key":"4695_CR149","unstructured":"Li Yujie CL, Zhongyuan Z, Hui L, Qian W, Ting Y, Shuiqing Q. Yang Yuanmin, inventor; Institute of Materia Medica of CACMS, assignee. A kind of artemisinin-based enhanced pharmaceutical composition for preventing or treating malaria. China 2020."},{"key":"4695_CR150","unstructured":"Zhang Shuqiu WR, Shi Nan Z, Li L, Qingxia W, Ruili. Ren Guolian, inventor; Shanxi Medical University, assignee. Nanoparticle for treating artemisinin-sensitive and resistant malaria, and preparation method and application thereof 2023."},{"key":"4695_CR151","unstructured":"Zhang Shuqiu WR, Shi Nan Z, Li L, Qingxia W, Ruili. Ren Guolian, inventor; Shanxi Medical University, assignee. Nanoparticle for treating artemisinin-sensitive and resistant malaria, and preparation method and application thereof. China 2023."},{"key":"4695_CR152","unstructured":"Chen Qijun ZY, Jiang, Ning. Li Xin, inventor; Shanxi Medical University, assignee. Preparation method and application of a heparin-targeted dihydroartemisinin-loaded antimalarial nanoliposome lyophilized powder drug. China 2025."}],"container-title":["Discover Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04695-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11671-026-04695-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04695-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:02:14Z","timestamp":1780329734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11671-026-04695-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":152,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4695"],"URL":"https:\/\/doi.org\/10.1186\/s11671-026-04695-3","relation":{},"ISSN":["2731-9229"],"issn-type":[{"value":"2731-9229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"233"}}